Document Detail


Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: Involvement of FOXO3a.
MedLine Citation:
PMID:  22713244     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Several lines of evidence suggest that the IκB kinase (IKK)/nuclear factor-κB (NFκB) axis is required for viability of leukemic cells and is a predictor of relapse in T-cell acute lymphoblastic leukemia (T-ALL). Moreover, many anticancer agents induce NFκB nuclear translocation and activation of its target genes, which counteract cellular resistance to chemotherapeutic drugs. Therefore, the design and the study of IKK-specific drugs is crucial to inhibit tumor cell proliferation and to prevent cancer drug-resistance. Here, we report the anti-proliferative effects induced by BMS-345541 (a highly selective IKK inhibitor) in three Notch1-mutated T-ALL cell lines and in T-ALL primary cells from pediatric patients. BMS-345541 induced apoptosis and an accumulation of cells in the G 2/M phase of the cell cycle via inhibition of IKK/NFκB signaling. We also report that T-ALL cells treated with BMS-345541 displayed nuclear translocation of FOXO3a and restoration of its functions, including control of p21 (Cip1) expression levels. We demonstrated that FOXO3a subcellular re-distribution is independent of AKT and ERK 1/2 signaling, speculating that in T-ALL the loss of FOXO3a tumor suppressor function could be due to deregulation of IKK, as has been previously demonstrated in other cancer types.   It is well known that, differently from p53, FOXO3a mutations have not yet been found in human tumors, which makes therapeutics activating FOXO3a more appealing than others. For these features, BMS-345541 could be used alone or in combination with traditional therapies in the treatment of T-ALL.
Authors:
Francesca Buontempo; Francesca Chiarini; Daniela Bressanin; Giovanna Tabellini; Fraia Melchionda; Andrea Pession; Milena Fini; Luca M Neri; James A McCubrey; Alberto M Martelli
Related Documents :
22436134 - Downregulation of hur as a new mechanism of doxorubicin resistance in breast cancer cells.
16453634 - Mutants of polysphondylium pallidum altered in cell aggregation and in the expression o...
17027864 - Anti-leukemic activities of dictyostelium secondary metabolites: a novel aromatic metab...
12499864 - Transient osmotic stress facilitates mutant huntingtin aggregation.
9228824 - Using acoustic radiation force as a concentration method for erythrocytes.
18432334 - Fabrication of a modular tissue construct in a microfluidic chip.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-01
Journal Detail:
Title:  Cell cycle (Georgetown, Tex.)     Volume:  11     ISSN:  1551-4005     ISO Abbreviation:  -     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-6-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101137841     Medline TA:  Cell Cycle     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Laboratory of Preclinical and Surgical Studies; Rizzoli Orthopedic Institute; Bologna, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lin28 regulates HER2 and promotes malignancy through multiple mechanisms.
Next Document:  Network analysis identifies a putative role for the PPAR and type 1 interferon pathways in glucocort...